Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology

Cancer

Volumn 111, Issue 6, 2007, Pages 517-524

  Daniely, Michal ^a   Rona, Roni ^b   Kaplan, Tal ^a   Olsfanger, Shirley ^b   Elboim, Lea ^b   Freiberger, Avner ^a   Lew, Sylvia ^b   Leibovitch, Ilan ^b  

^a BIOVIEW LTD   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Automatic scanning system; Bladder cancer; Combined analysis; Cytology; Fluorescence in situ hybridization (FISH); Transitional cell carcinoma (TCC)

Indexed keywords

ADULT; AGED; ARTICLE; AUTOMATION; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CELL STRUCTURE; CYSTOSCOPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYMPTOM; URINALYSIS; URINE CYTOLOGY;

CYTODIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 37349115573     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23119     Document Type: Article

References (24)

1. Dalquen P, Kleiber B, Grilli B, Herzog M, Bubendorf L, Oberholze M. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer (Cancer Cytopathol). 2002;96:374-379.
2. Dyrskjot L. Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarray in cancer diagnostics. Expert Rev Mol Diagn. 2003;3:635-647.
3. Jung I, Reeder JE, Cox C, et al. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol. 1999;162:1900-1903.
4. Phillips JL, Richardson IC. Aneuploidy in bladder cancer: the utility of fluorescence in situ hybridization in clinical practice. BJU Int. 2006;98:33-37.
5. Bubendorf L, Grilli G, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79-86.
6. Raitanen MP, Kaasinen E, Lukkarinen O, et al. Analysis of false-positive BTA Stat test results in patients followed up for bladder cancer. Urology. 2001;57:680-684.
7. Jones SJ. DN. A-based molecular cytology for bladder cancer surveillance. Urology 2006;67(Suppl 3A):35-47.
8. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyte: a new tool for detecting transitional cell cancer of the urinary tract. J Urol. 1999;161:1486-1489.
9. Ishiwata S, Takahashi S, Homma Y, et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology. 2001;57:811-815.
10. Hailing KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
11. Halachmi S, Madeb R, Kravtsov A, Moskovitz B, Halachmi N, Nativ O. Bladder cancer - genetic overview. Med Sci Monit. 2001;7:164-168.
12. Sandberg AA. Cytogenetics and molecular genetics of bladder cancer: a personal view. Am J Med Genet. 2002;115:173-182.
13. Tsukamoto M, Matsuyama H, Oba K, Yoshihiro S, Takahashi M, Naito K. Numerical aberrations of chromosome 9 in bladder cancer: a possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet. 2002;134:41-45.
14. Marano A, Pan Y, Li C, et al. Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer. Eur Urol. 2000;37:358-365.
15. Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005;173:401-404.
16. Sokolova IA, Hailing KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123.
17. Veeramachaneni R, Nordberg ML, Shi R, Herrera GA, Turbat-Herrera EA. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol. 2003;28:301-307.
18. Daniely M, Rona R, Kaplan T, et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology. 2005;66:1354-1359.
19. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448.
20. Bielorai B, Golan H, Trakhtenbrot L, et al. Combined analysis of morphology and fish in follow-up of minimal residual disease (MRD) in a child with Ph+ acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet. 2002;138:64-68.
21. Kaplinsky C, Trakhtenbrot L, Hardan I, et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSFM. Bone Marrow Transplant. 2003;32:31-34.
22. Shimoni A, Nagler A, Kaplinsky C, et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (DuetTM) combined morphological and cytological analysis. Leukemia. 2002;16:1413-1418.
23. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101-2105.
24. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res. 2006;114:279-283.